Scientists have discovered a way to make gene editing safer and more precise — and it's an advance that could help bolster ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
MedPage Today on MSN
Gene-Editing Therapy Promising for Rare Hereditary Disease
A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...
Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.
Magnesium is essential to Cas9’s function, but many studies on the protein are done in a solution with a magnesium ...
Development of bespoke therapies has been a driving goal in medical research. This year, the announcement of the first patient treated with personalized CRISPR therapy, Baby KJ, highlights this ...
Insider Monkey on MSN
CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...
MedPage Today on MSN
What Are the Goalposts for Present and Future ATTR-CM Therapies?
This spring, the gene-silencing therapy vutrisiran (Amvuttra) joined the transthyretin (TTR) stabilizers tafamidis (Vyndamax) ...
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback